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Renal anemia in chronic kidney disease is treated with recombinant human
erythropoietin (rhEPO). However, some patients with anemia do not
respond well to rhEPO, emphasizing the need for a more biocompatible
EPO. Differentiation protocols for hepatic lineages have been modified to
enable production from human induced pluripotent stem cell (hiPSC)-
derived EPO-producing cells (EPO cells). However, markers for hiPSC-
EPO cells are lacking, making it difficult to purify hiPSC-EPO cells and
therefore to optimize EPO production and cell counts for transplantation.
To address these issues, we investigated whether CD140b and CD73 could
be used as markers for hiPSC-EPO cells. We measured the expression of
EPO, CD140b, and CD73 in hiPSC-EPO cells and the EPO concentration
in the cell supernatant by immunohistochemistry and enzyme-linked
immunosorbent assays on culture day 13, revealing that expression levels
of CD140b and CD73 are correlated with the level of EPO. In addition,
rates of CD140b+ CD73+ cells were observed to be correlated with the con-
centration of EPO. Thus, our results suggest that CD140b and CD73 may
be markers for hiPSC-EPO cells.
Erythropoietin (EPO) has an essential role in erythro-
poiesis [1]. The kidney is the main organ for EPO pro-
duction in adults; however, EPO production is severely
reduced in patients with chronic kidney disease (CKD)
[2]. To improve renal anemia, patients with CKD are
treated with recombinant human EPO (rhEPO).
Although rhEPO improves renal anemia and mortality
in patients with CKD, patients have to receive rhEPO
infusions one to three times per week to maintain the
erythropoiesis level [3,4]. In addition, it is necessary to
consider the total cost of rhEPO.
A previous report has suggested that patients with
anemia secondary to chronic diseases may not respond
well to rhEPO [5]. In very rare cases, patients with
germline mutations in EPO [6] or with anti-rhEPO
autoantibodies after treatment with rhEPO have been
reported [7,8]. To solve these problems, it is necessary
to develop a more biocompatible EPO.
Abbreviations
CKD, chronic kidney disease; hiPSC, human induced pluripotent stem cell; KSR, KnockOut Serum Replacement; NCCLS, National
Committee for Clinical Laboratory Standards; NEAA, nonessential amino acid; PBST, PBS/0.1% Triton X-100; rhEPO, recombinant human
erythropoietin.
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We have modified a previously reported differentiation
protocol for hepatic lineages to establish a protocol
for generating human induced pluripotent stem cell
(hiPSC)-derived EPO-producing cells (EPO cells) [9].
hiPSC-EPO cells were more beneficial for the treat-
ment of renal anemia in mice with CKD than rhEPO
[9]. However, for transplantation, over 1.0 9 107
iPSC-EPO cells per mouse were needed. In addition,
markers for hiPSC-EPO cells have not been identified;
therefore, there are no methods for the purification of
hiPSC-EPO cells. To enable the application of hiPSC-
EPO cells in regenerative medicine, the identification
of markers for hiPSC-EPO cells and the purification of
hiPSC-EPO cells are needed to optimize EPO produc-
tion and the number of hiPSC-EPO cells for transplan-
tation. Previous studies have suggested that CD140b
and CD73 are markers for renal EPO cells [10–12].
Since these proteins are expressed on the surfaces of
cells, if they are also expressed in hiPSC-EPO cells, a
cell sorting approach can be used for isolation. In
addition, hiPSC-EPO cells are differentiated from hiPS
cells cultured on feeder cells. To avoid xenotransplan-
tation, a differentiation protocol from hiPSCs cultured
by the nonfeeder culture system should be established.
Accordingly, we investigated whether CD140b and
CD73 are markers for EPO cells differentiated from
hiPSCs obtained by a feeder-free culture system.
Methods
hiPSC culture
The hiPSCs (253G1) were provided by the RIKEN BRC
through the Project for Realization of Regenerative Medi-
cine and the National Bio-Resource Project of the MEXT,
Japan. The hiPSCs were cultured under feeder-free condi-
tions according to a previous report [13]. Briefly, hiPSCs
were seeded on plates coated with iMatrix-511 (Nippi,
Tokyo, Japan). hiPSCs were incubated in StemFit medium
supplemented with Y-27632 (10 µM; Wako, Osaka, Japan)
for the first 24 h, and the medium was replaced with Stem-
Fit medium without Y-27632. The StemFit medium was
replaced with fresh medium every other day until culture
day 7. After day 7, hiPSCs were used for differentiation
protocols to obtain EPO cells.
Differentiation protocols for hiPSC-EPO cells
The differentiation of EPO cells from hiPSCs was per-
formed according to a previously reported protocol, with
modifications (Fig. 1). hiPSCs harvested in StemFit med-
ium were dissociated to single cells by gentle pipetting after
treatment with Accutase (Innovative Cell Technologies, San
Diego, CA, USA) for 2 min at 37 °C and seeded on
Matrigel (Corning, Inc., Corning, NY, USA)-coated plates
at a density of 5.0 9 104 cellscm2 with stage 1 medium
containing RPMI 1640 (Nacalai Tesque, Kyoto, Japan)
supplemented with B27 supplement (Thermo Fisher Scien-
tific, Waltham, MA, USA), recombinant human/mouse/rat
activin A (100 ngmL1) (PeproTech Inc., Princeton, NJ,
USA), and 1 lM CHIR99021 (Wako). Y-27632 (10 µM;
Wako) was added to the stage 1 medium for the first 24 h.
After 24 h, this medium was changed to the fresh medium
without Y-27632 until culture day 3. On culture day 3, the
medium was changed to stage 2 medium containing Knock-
Out DMEM (Thermo Fisher Scientific) supplemented with
penicillin/streptomycin (25 UmL1), 20% KnockOut
Serum Replacement (KSR), 1% DMSO, 2 mM L-glutamine,
1% nonessential amino acid (NEAA), and 100 lM b-mer-
captoethanol. Stage 2 medium was replaced every day until
culture day 5. After culture day 7, stage 2 medium was
replaced with fresh medium every other day until culture
day 13.
Immunocytochemistry
EPO, CD140b, and CD73 on hiPSC-EPO cells, and
CD140b and CD73 on hiPSCs were evaluated by immuno-
cytochemistry. Immunostaining of EPO was performed
according to previously described methods [9]. In brief,
hiPSC-EPO cells were fixed with 4% paraformaldehyde/
PBS for 20 min at 4 °C. After washing with PBS, the cells
were permeabilized by PBST (PBS/0.1% Triton X-100) for
20 min at room temperature (18–25 °C). To block Fc
receptors, the cells were incubated with 3% TruStain
FcXTM (Biolegend, San Diego, CA, USA) for 10 min at
room temperature after permeabilization. The cells were
then incubated with mouse anti-human EPO antibody
(Merck Millipore, Burlington, MA, USA) overnight at
4 °C followed by a conjugate of Alexa 488-labeled poly-
clonal goat anti-mouse IgG antibody (Biolegend). After
washing, a PE-labeled rat monoclonal anti-CD73 antibody
(Biolegend) or an APC-labeled rat monoclonal anti-
CD140b antibody (Biolegend) was applied for 30 min at
room temperature. After washing with PBS, images were
captured at 9100 magnification using a BZ-X700 Fluores-
cence Microscope (Keyence, Osaka, Japan). The hiPSC-
EPO cells treated with TruStain FcXTM were used as a
background control, and then, the positive areas for EPO,
CD140b, and CD73 were measured using Image Express
(Molecular Devices, San Jose, CA, USA) in 20 sequential
fields, and values were obtained.
Fluorescent-activated cell sorting
To quantify CD140b+ CD73+ cells, hiPSC-EPO cells were
dissociated to single cells by treatment with Accutase for
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10 min at 37 °C. After washing with PBS, the cells were
incubated with 3% TruStain FcXTM for 10 min at room
temperature. Then, the cells were incubated with a PE-la-
beled mouse monoclonal anti-CD73 antibody and an APC-
labeled mouse monoclonal anti-CD140b antibody for
30 min at room temperature. After washing with PBS con-
taining 1% FBS, fluorescent-activated cell sorting was per-
formed using a BD LSR Fortessa X-20 System (Becton
Dickinson, Franklin Lakes, NJ, USA) to detect expressions
of CD140b and CD73 on the cell surface.
Enzyme-linked immunosorbent assay
The concentrations of EPO in the medium were measured
by ELISA according to the manufacturer’s protocol
(ALPCO Diagnostics, Salem, NH, USA). In brief, the
culture medium of hiPSC-EPO cells was added to a 96-well
plate with enzyme-labeled anti-human EPO antibodies and
incubated for 2 h at room temperature. The substrate was
then incubated on the plate for 30 min, and the reaction
was stopped with 0.5 mM sulfuric acid. The plates were
read at 450 nm using the iMarkTM Microplate Reader (Bio-
Rad, Hercules, CA, USA), and the concentration of EPO
was calculated on the basis of the standard curve for lyo-
philized synthetic EPO.
Statistical analyses
Comparisons among multiple groups were conducted by
one-way ANOVA followed by Bonferroni’s tests. A corre-
lation analysis was performed by Pearson’s (parametric
parameters) or Spearman’s (nonparametric parameters)
Fig. 1. Erythropoietin concentration in the supernatant and overview of the modified differentiation protocol. The differentiation protocol was
performed by modifying a previous method [9]. hiPSCs grown on plates coated with iMatrix-511 were cultured in StemFit medium for
7 days. The hiPSCs were dissociated to single cells by gentle pipetting after treatment with Accutase and seeded on Matrigel-coated plates
with stage 1 medium containing RPMI 1640 supplemented with B27 supplement, recombinant human/mouse/rat activin A, and 1 lM
CHIR99021. After 24 h, this medium was replaced with fresh medium without Y-27632 until culture day 3. The medium was changed to
stage 2 medium containing KnockOut DMEM supplemented with penicillin/streptomycin, 20% KSR, 1% DMSO, 2 mM L-glutamine, 1%
NEAA, and 100 lM b-mercaptoethanol. The hiPSCs were stained with anti-CD140b (red color) and anti-CD73 (green color) antibodies. The
white bar indicates 100 µm. EPO concentrations are shown as mean values  SD. **P < 0.01 vs. day 5 (Bonferroni’s test).
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methods. A two-sided P-value of < 0.05 was considered
significant. SPSS v22.0 (SPSS, Chicago, IL, USA) was used
for statistical analyses.
Results
hiPSC-EPO cells secreted erythropoietin
We previously reported that EPO secretion from hiPSC-
EPO cells peaks on culture days 11–13 [9]. In the present
study, hiPSCs were cultured by a feeder-free culture sys-
tem (Fig. 1) for differentiation to hiPSC-EPO cells. The
peak of EPO secretion by hiPSC-EPO cells was detected
on culture day 13. According to the National Commit-
tee for Clinical Laboratory Standards (NCCLS), the ref-
erence range for the EPO concentration in human
serum is 3.22–31.9 mIUmL1. The levels exceeded
3.22 mIUmL1 on culture days 9 and 13, which were
within this reference range.
CD140b and CD73 were correlated with the
concentration of erythropoietin
To investigate whether CD140b and CD73 could be
markers for hiPSC-EPO cells, we evaluated correla-
tions between CD140b or CD73 and EPO on hiPSC-
EPO cells. The expressions of CD140b and CD73 on
hiPSCs were negative (Fig. 1). The expression of
CD73 was correlated with the expression of EPO
(R = 0.993, P < 0.001) and the concentration of EPO
in the cell supernatant (R = 0.944, P = 0.001) (Fig. 2).
The expression of CD140b was correlated with the
expression of EPO (R = 0.871, P = 0.024) and the con-
centration of EPO in the supernatant (R = 0.985,
P < 0.001) (Fig. 3). These results suggested that
CD140b and CD73 are markers for hiPSC-EPO cells.
Rates of CD140b+ CD73+ cells were correlated
with the concentration of erythropoietin
For the purification for hiPSC-EPO cells, we evaluated
the correlations between the rates of CD140b+ CD73+
cells and the concentration of EPO in the supernatant.
The rates of CD140b+, CD73+, and CD140b+ CD73+
cells were correlated with EPO in the supernatant
(R = 0.943, P < 0.01; R = 0.829, P < 0.05; R = 0.943,
P < 0.01, respectively) (Fig. 4). These results suggested
that CD140b and CD73 are targets for cell sorting.
Discussion
We previously established a differentiation protocol
for hiPSC-EPO cells [9] using hiPSCs cultured by a
feeder culture system. Although feeder cells are widely
Fig. 2. Correlation between EPO and CD73 expression. EPO and CD73 expressions were evaluated by immunocytochemistry. The hiPSC-
EPO cells were stained with anti-EPO (green) and anti-CD73 antibodies (red). The white bar indicates 100 µm. The P-values were
determined by Pearson’s tests.
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used to maintain and culture hiPSCs, the preparation
of feeder cells is time-consuming. In addition, to sat-
isfy the Standard for Biological Ingredients, FBS-con-
taining medium should be removed entirely. We
established a differentiation protocol for hiPSC-EPO
cells produced from hiPSCs cultured in feeder-free
conditions. We investigated whether hiPSC-EPO cells
generated by the new differentiation protocol can pro-
duce EPO and found that the EPO concentration was
within the reference range recommended by the
NCCLS. Although further studies are needed to verify
these findings, they suggest that hiPSC-EPO cells were
successfully produced from hiPSCs in feeder-free con-
ditions.
In our previous report, hiPSC-EPO cells ameliorated
renal anemia in CKD mice; however, optimization of
the number of hiPSC-EPO cells needed purification.
Recent reports have suggested that CD140b and CD73
are markers for EPO cells [10–12]. Our previous differ-
entiation protocol was established for hiPSCs/embry-
onic stem cells through hepatic lineage differentiation,
and it was not clear whether hiPSC-EPO cells have
similar characteristics. In addition, markers for hiPSC-
EPO cells were lacking. Accordingly, we investigated
whether hiPSC-EPO cells express CD140b and CD73.
In Fig. 4, the rates of CD140b+ cells are higher than
those of CD140b+ CD73+ cells. This result indicated
that CD73- cells would be included in CD140b+ cell.
Moreover, the correlation coefficient between CD73+
cells and EPO secretion was higher than that of
CD140b+ cells. To exclude CD140b+ CD73- cells, we
evaluated the correlation between the rate of CD140b+
CD73+ cells and EPO secretion in the medium. The
rates of CD140b+ CD73+ cells correlated with EPO
secretion. These results suggested that CD140b+
CD73+ cells produce EPO. In addition, these proteins
are expressed on cell surfaces. To remove CD140b-
CD73- cells, which would be positive for hepatic lin-
eage and endoderm markers [9], CD140b and CD73
might be useful for the purification by cell sorting. For
the purification and optimization of hiPSC-EPO cells,
CD140b and CD73 should be used for sorting in fur-
ther studies.
We proposed a modified differentiation protocol for
hiPSC-EPO cells. However, our study had some limi-
tations. First, we did not investigate whether hiPSC-
EPO cells ameliorated renal anemia in CKD mice. Sec-
ond, we did not measure the EPO concentration in
low-oxygen conditions. To show that the hiPSC-EPO
cells generated by our approach have the same
Fig. 3. Correlation between CD140b and erythropoietin expression. EPO and CD140b expressions were evaluated by
immunocytochemistry. hiPSC-EPO cells were stained with anti-EPO (green) and anti-CD140b antibodies (red). The white bar indicates
100 µm. The P-values were determined by Pearson’s tests.
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function as EPO cells, further studies are needed. In
conclusion, our results suggested that CD140b and
CD73 are beneficial to cell surface markers for hiPSC-
EPO cells.
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